目的 探讨天麦消渴片联合西格列汀治疗肥胖型2型糖尿病的临床效果。方法 选取荥阳市人民医院2015年1月-2017年1月收治的肥胖2型糖尿病患者116例，随机分成对照组和治疗组，每组各58例。对照组患者口服磷酸西格列汀片，1片/次，1次/d。治疗组在对照组的基础上口服天麦消渴片，2片/次，2次/d。所有患者均治疗12周。观察两组患者临床疗效，比较治疗前后两组患者糖尿病相关指标、炎性指标和不良反应情况。结果 治疗后，对照组和治疗组临床总有效率分别为81.03%、96.55%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者体质量指数（BMI）、空腹血糖（FBG）、糖化血红蛋白（HbA1c）均显著性降低，稳态模型胰岛素分泌指数（HOMA-β）显著升高，同组比较差异具有统计学意义（P<0.05）；且治疗组这些指标的改善情况均要优于对照组患者，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者C反应蛋白（CRP）、内皮素-1（ET-1）、血栓素A2（TXA2）、NO、IL-6水平均明显降低（P<0.05）；且治疗组患者各项炎性指标均要明显低于对照组（P<0.05）。结论 天麦消渴片联合西格列汀治疗肥胖2型糖尿病疗效显著，安全可靠，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Tianmai Xiaoke Tablets combined with sitagliptin in treatment of obesity type 2 diabetes. Methods Patients (116 cases) with obesity type 2 diabetes in Xingyang People's Hospital from January 2015 to January 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Tianmai Xiaoke Tablets on the basis of the control group, 2 tablets/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, the diabetes related indicators, inflammatory markers and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.03% and 96.55%, respectively, and there were differences between two groups (P<0.05). After treatment, the BMI, FBG and HbA1c in two groups was significantly decreased, but HOMA-β was significantly increased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the CRP, ET-1, TXA2, NO, IL-6 levels in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the inflammatory markers levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Tianmai Xiaoke Tablets combined with sitagliptin has significant effect in treatment of obesity type 2 diabetes with high safety, which has a certain clinical application value.